BioForce Nanosciences (OTCMKTS: BFNH – Get Rating) is one of 42 public companies in the “Analytical Instruments” sector, but how does it compare to its competitors? We will compare BioForce Nanosciences to related companies based on its risk strength, earnings, profitability, institutional ownership, analyst recommendations, valuation and dividends.

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of BioForce Nanosciences and its rivals.

Gross revenue Net revenue Price/earnings ratio
BioForce Nanosciences $20,000.00 -$500,000.00 -205.00
Competitors BioForce Nanosciences $1.16 billion $344.59 million -24.91

BioForce Nanosciences rivals have higher revenues and profits than BioForce Nanosciences. BioForce Nanosciences trades at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and insider ownership

60.8% of the shares of all “Analytical Instruments” companies are held by institutional investors. 39.5% of the shares of BioForce Nanosciences are held by insiders of the company. By comparison, 13.4% of the shares of all Analytical Instruments companies are held by insiders of the company. Strong institutional ownership indicates that endowments, large fund managers, and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BioForce Nanosciences and its rivals, as provided by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
BioForce Nanosciences 0 0 0 0 N / A
Competitors BioForce Nanosciences 147 960 1633 50 2.57

As a group, the “Analytical Instruments” companies have an upside potential of 49.34%. Since the rivals of BioForce Nanosciences have higher upside potential, analysts clearly believe that BioForce Nanosciences has less favorable growth aspects than its rivals.

Volatility and risk

BioForce Nanosciences has a beta of -1.49, indicating that its stock price is 249% less volatile than the S&P 500. Comparatively, rivals BioForce Nanosciences have a beta of 1.21, indicating that their average price is 21% more volatile than the S&P. 500.


This table compares the net margins, return on equity and return on assets of BioForce Nanosciences and its competitors.

Net margins Return on equity return on assets
BioForce Nanosciences N / A N / A -2,538.94%
Competitors BioForce Nanosciences -250.85% 6.38% -11.11%


Rivals BioForce Nanosciences beat BioForce Nanosciences on 7 of the 9 factors compared.

BioForce Nanosciences Company Profile (Get a rating)

BioForce Nanosciences Holdings, Inc. is focused on providing natural vitamins, minerals, other nutritional supplements, powders and beverages for people of different age groups. The company offers private label products with distributors and manufacturing suppliers. It sells its nutritional supplements to retailers, sporting goods retailers, supermarkets and mass merchandisers under the BioForce Eclipse brand, as well as online and through telemarketing. The company is based in Virginia Beach, Virginia.

Get news and reviews for BioForce Nanosciences Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for BioForce Nanosciences and related companies with’s FREE daily newsletter.